George S. Golumbeski

George S. Golumbeski, Ph.D. has served as a member of the board of directors since February 2014. Dr. Golumbeski is an independent biotechnology advisor since August 2019 and previously served as President of GRAIL, Inc., a privately-held biotechnology company, since August 2018. From 2017 until April 2018, Dr. Golumbeski was the Executive Vice President for Innovation for Celgene Corporation, a biotechnology company, where he was previously Executive Vice President of Business Development since 2009, responsible for the full array of business development activities and focused primarily within the therapeutic areas of oncology and inflammation. From 2008 to 2009, Dr. Golumbeski served as the CEO of Nabriva Therapeutics AG. Prior to Nabriva, Dr. Golumbeski served as Vice President of Business Development, Licensing and Strategy for Novartis-Oncology. Earlier in his career, Dr. Golumbeski held senior positions at Elan Pharmaceuticals and at Schwarz Pharma. He currently serves on the Boards of Directors of MorphoSys AG and Sage Therapeutics, public biotechnology companies. Dr. Golumbeski received a B.A. in biology from the University of Virginia and a Ph.D. in genetics from the University of Wisconsin-Madison.